Alendronate/vitamin D3 70Â mg/2800Â IU with and without additional 2800Â IU vitamin D3 for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial

Although vitamin D supplementation is a fundamental part of osteoporosis treatment, many patients do not regularly take adequate amounts. A once-weekly (OW) alendronate (ALN) preparation that includes 2800 IU of vitamin D3 in a single combination tablet (ALN + D2800) is available for treating patients and ensuring intake of vitamin D that is consistent with existing guidelines.This randomized, double-blind study extension was conducted to evaluate the safety and tolerability of ALN + D2800 and ALN + D2800 plus an additional 2800 IU vitamin D3 single tablet supplement (ALN + D5600) administered for 24 weeks in men and postmenopausal women with osteoporosis previously treated OW for 15 weeks with either ALN or ALN + D2800. The primary endpoint was the proportion of participants who developed hypercalciuria (defined as a 24-hour urine calcium > 300 mg in women or > 350 mg in men and an increase of > 25% versus randomization baseline) at week 39. The key secondary endpoint was the proportion of participants with vitamin D insufficiency (serum 25(OH)D < 15 ng/mL [37.4 nmol/L]) at the end of the study.Hypercalciuria incidence (4.2% [ALN + D5600] vs. 2.8% [ALN + D2800]), did not differ between groups (p = 0.354). No participants developed hypercalcemia. Among the participants with vitamin D insufficiency at the week 0 baseline, the prevalence of insufficiency at the end of the study was reduced by 92% in the ALN + D5600 group and by 86% in the ALN + D2800 group. The incidences of clinical adverse experiences, including drug-related adverse experiences, were similar in both groups.In subjects previously treated with ALN + D2800 for 15 weeks, the addition of 2800 IU D3 for 24 weeks did not produce hypercalcemia nor increase the risk of hypercalciuria.